Monday, June 3rd, 2019

9:30 - 9:40  WELCOME ADDRESS

9:45 – 10:00:  Avid Mohammadi
Characterizing the impact of penile-vaginal sex on HIV-susceptible CD4+ T cell subsets in the female genital tract

10:05 - 10:20:  Erin O. Y. Wong
Developing defined microbiota to model inflammation in the mouse gut

10:25 - 10:40:  Nora Mellouk
An ATG16L1-dependent pathway promotes plasma membrane repair and limits Listeria monocytogenes cell-to-cell spread

10:45 - 11:15:  COFFEE BREAK

11:20 - 11:35:  Jean-Paul R. Soucy
Joint modelling of resistance to six antimicrobials in urinary Escherichia coli isolates in Quebec, Canada

11:40 – 11:55:  Sarah Birstonas
EHEC utilizes two-component systems to modulate expression of major flagellar subunit protein, FlIC, in response to host intestinal cues

12:00 - 12:15:  Nathaniel Winsor
NLRP6 regulates the colonic mucus layer during Tritrichomonas infection

12:35 – 1:30: LUNCH

1:35 - 12:50:  Samuel Salamun
Epstein-Barr Virus Protein BMRF1 Modulates Cellular SUMO and DNA Damage Response Pathways by Binding the Cellular NuRD Complex

1:55 - 2:10:  Nicola Case
Elucidating the mechanism of Candida albicans morphogenesis in response to phagocytosis by macrophages

2:15 - 2:30:  Sarah Kronheim
A small molecule anti-phage defense mechanism in Streptomyces

2.30 - 3:00:  COFFEE BREAK

3:05 - 3:20:  Alexandra Willis
Understanding inherited immunity using a C. elegans model of microsporidia infection

3:25 - 3:40:  Genevieve Mailhot
Differentiating between protective and pathogenic neutrophil responses during Neisseria gonorrhoeae infection

3:45 – 4:00:  Tiffany Fitzpatrick
Successes of anti-RSV prophylaxis among infants in Ontario: results from a multi-decade, population-based controlled interrupted time series analysis using health administrative data
Poster Presentations
Ethnopharmaceuticals for the Treatment of Old World Cutaneous Leishmaniasis: A Systematic Review of Topical Application of Tumeric

Priyanka Challa

1Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada 2Public Health Ontario Laboratories, Toronto, ON, Canada 3Instituto de Medicina Tropical "Alexander von Humboldt", Lima, Peru 4Tropical Disease Unit, UHN-Toronto General Hospital, Toronto, ON, Canada

Toxicity, expense, and accessibility limit treatment success in Old World Cutaneous Leishmaniasis (OWCL), a neglected parasitic disease caused by members of the genus Leishmania found in the Middle East, Mediterranean basin, Arabian Peninsula, Africa as well as the Indian Subcontinent. Better drugs are urgently needed, however, drug discovery is hindered by limited funding given geographic restriction of highly endemic OWCL to LMICs. Plant-based compounds with potential anti-leishmanial effects found in and around local endemic communities present an opportunity to overcome the aforementioned therapeutic challenges, and many such interventions are supported by anecdotal evidence of efficacy. We aim to synthesize existing evidence around available ethnopharmaceuticals to promote drug discovery for the prevention and treatment of OWCL. PubMed (NCBI), Medline (OVID), Embase (OVID), Web of Science (BioSIS) and LILACS (VHL) were searched for from inception to July 26, 2018 using combinations of the search terms "cutaneous leishmaniasis" and "ethnopharmaceuticals". Iterative inclusion and exclusion of search terms was employed to maximize relevant article extraction. The GRADE approach will be used to assess quality of studies reporting therapeutic interventions. 3057 PubMed, 2818 Medline, 4200 Embase, 3183 Web of Science and 490 LILACS articles were retrieved for title and abstract screening; after duplicate removal, 5492 remained. 550 abstracts met inclusion criteria for full-text review, of which, 241 (43.80%) abstracts pertained to Old World species, and 113 (21%) were specific to L. donovani. Curcuma spp. “Turmeric” was identified in 4 articles (0.7%) to date. Synthesizing the current evidence surrounding ethnopharmaceuticals for the treatment of OWCL may contribute to drug discovery pipelines and potentially lead to novel therapeutics in a field that has not seen any new drug development for over half a century, especially in the context of turmeric.